{
  "nctId": "NCT02634710",
  "briefTitle": "Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall",
  "officialTitle": "Pilot Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall",
  "protocolDocument": {
    "nctId": "NCT02634710",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-04-05",
    "uploadDate": "2023-03-14T14:38",
    "size": 482194,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02634710/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 35,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-02-23",
    "completionDate": "2022-06-14",
    "primaryCompletionDate": "2022-05-18",
    "firstSubmitDate": "2015-11-04",
    "firstPostDate": "2015-12-18"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* ≥ 18 years of age\n* Core needle biopsy obtained\n* Pathologic confirmation of primary soft tissue sarcoma of the upper or lower extremity or chest-wall.\n* Stage I-III Soft Tissue Sarcoma of the extremity without evidence of metastatic disease\n* Medically operable\n* No prior radiotherapy to primary site or adjacent site that results in overlapping radiation fields.\n* MRI obtained of the affected extremity or chest-wall\n* CT chest acquired to assess distant disease\n* Karnofsky Performance Status (KPS) 60 or above\n* Informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* Patients who have metastatic disease\n* Pregnant women\n* Women of childbearing potential and male participants must practice adequate contraception.\n* Disease pathology other than sarcoma subtypes\n* Patients with a history of metastatic disease from a primary other than sarcoma\n* Patients who cannot undergo MRI as part of pre-treatment or treatment planning process\n* STS of non-extremity or chest-wall regions\n* Tumor size ≥ 20 cm maximal dimension",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Local Disease Control Assessed by Physical Examination",
        "description": "This measure will capture the number of subjects experiencing a recurrence of the primary lesion assessed by physical examination.",
        "timeFrame": "2 Years"
      },
      {
        "measure": "Local Disease Control Assessed by Magnetic Resonance Imaging (MRI)",
        "description": "This measure is the number of subjects experiencing a recurrence of the primary lesion as assessed by MRI.",
        "timeFrame": "2 years"
      }
    ],
    "secondary": [
      {
        "measure": "Musculoskeletal Tumor Rating Scale (MSTS) Score",
        "description": "Toxicity will be assessed at specific times the Musculoskeletal Tumor Rating Scale. The MSTS evaluates: pain, function, emotional acceptance, hand positioning, dexterity and lifting ability, using a six-item Likert scale ranging from 0 (worst condition) to 5 (best condition). The individual scores are added for the MSTS Score, range 0 to 30. A higher score indicates better function.",
        "timeFrame": "Baseline, prior to surgery and 24 months after surgery"
      },
      {
        "measure": "Disease-free Survival",
        "description": "Disease-free survival will measure the time in months from initiation of radiation therapy until documented recurrence of disease. Patients who are disease-free and alive at the time of analysis will be censored at the time of their last follow-up. Patients will be assessed for disease-free survival at 2 years.",
        "timeFrame": "2 Years"
      },
      {
        "measure": "Overall Survival",
        "description": "Overall survival will measure the time from initiation of radiation therapy until documented death from any cause. Patients who are alive at the time of analysis will be censored at the time of their last follow-up. Patients will be assessed for overall survival at 2 years.",
        "timeFrame": "2 Years"
      },
      {
        "measure": "Radiologic Changes Due to Hypofractionated Radiation.",
        "description": "This measure will assess the size of enhancement due to hypofractionated radiation.",
        "timeFrame": "4 weeks after radiation therapy"
      },
      {
        "measure": "Pathologic Changes Due to Hypofractionated Radiation.",
        "description": "This measure will capture the fibrosis present in tissue specimens as a percent.",
        "timeFrame": "2 weeks after surgery"
      },
      {
        "measure": "Treatment-related Necrosis and Fibrosis",
        "description": "Number of participants who experienced treatment-related necrosis and fibrosis ≥90%.",
        "timeFrame": "2 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 8
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:53.965Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}